Needham Reiterates Buy on Cormedix, Maintains $15 Price Target

Needham analyst Serge Belanger has reiterated a Buy rating on Cormedix (NASDAQ: CRMD) and maintained a price target of $15 for the stock. This endorsement reflects confidence in the company's performance and potential for growth.